PRKAR1A mutations and loss of PRKAR1A protein expression are seen in most cases and should prompt a search for other findings of the Carney complex [3, 4]
Importantly, the nuance in offering GLP-1s is that employers want to ensure they get into the hands of the employees that stand to benefit most and thus get the most value out of the medicines, so I expect we will see additional restrictions put in place to control coverage of these medicines, in the form of prior authorizations and other controlled access
Im confused at this, so how do you calculate exactly how much volume does L carn takes up
For information about how Linzess performed in clinical trials, see the drugs prescribing information
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V et al